

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



PI Duan DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;  
 XX MPI; 2000-431566/37.  
 DR P-PSDB; AAB24458.  
 XX  
 PT Forty seven human nucleic acids encoding secreted proteins, useful in  
 PT the treatment, prevention and diagnosis of cancers, disorders of the  
 PT immune system, angiogenesis disorders, neurological diseases and  
 PT hyperproliferative disorders -

PS Claim 1; Page 457-458; 562pp; English.

XX  
 CC The polynucleotide sequence given in AAA78381 to AAA78432 encode the  
 CC human secreted proteins given in AAB24437 to AAB24604. Human secreted  
 CC proteins have activities based on the tissues and cells the genes are  
 CC expressed in. Examples of activities include: cytostatic; antineoplastic;  
 CC antidiabetic; antiinflammatory; ophthalmological; antihemetic;  
 CC antirheumatic; antipsoriatic; antiangiogenic; cardiant; anti-HIV;  
 CC neurotropic; neuroprotective; antimicrobial and antiparkinsonian.  
 CC Human secreted protein polynucleotides, polypeptides, antagonists and/or  
 CC agonists may be useful in treating, preventing, and/or diagnosing other  
 CC diseases, disorders, and/or conditions such as: (a) cancers; (b)  
 CC disorders of the immune system; (c) angiogenesis disorders; (d)  
 CC hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases  
 CC associated with increase apoptosis; (g) neurological diseases; and  
 CC (h) infectious diseases. They are also used to promote wound healing.  
 CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the  
 CC exemplification of the present invention.  
 CC  
 XX

SO Sequence 1461 BP; 428 A; 312 C; 324 G; 397 T; 0 other;

Query Match 100.0%; Score 570; DB 21; Length 1461;

Best local similarity 100.0%; Pred. No. 1.9e-166;

Matches 570; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGGGGCTTCACAGATGACTTTCTTC 60  
 DB 63 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGGGGCTTCACAGATGACTTTCTTC 122  
 QY 61 ATCTCTTGGCTTTTCCATCTTTCACGGGGGCTTGGACACCTGGGCATACCATC 120  
 DB 123 ATCTCTTGGCTTTTCCATCTTTCACGGGGGCTTGGACACCTGGGCATACCATC 182  
 QY 121 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTCGAGGCTGCCCTCTTCATTTCAC 180  
 DB 183 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTCGAGGCTGCCCTCTTCATTTCAC 242  
 QY 181 TCCATCTACAGCTTGATCGACACCTTAAGTACACGGCCTGGCTACCTGTGGTTTGG 240  
 DB 243 TCCATCTACAGCTTGATCGACACCTTAAGTACACGGCCTGGCTACCTGTGGTTTGG 302  
 QY 241 ATCATGGAAGCTCATTTGGAAGTGTGACCTTTTTCATCCCTCACCCTCATTTGTGCTA 300  
 DB 303 ATCATGGAAGCTCATTTGGAAGTGTGACCTTTTTCATCCCTCACCCTCATTTGTGCTA 362  
 QY 301 ATCATGGAAGCTCATTTGGAAGTGTGACCTTTTTCATCCCTCACCCTCATTTGTGCTA 360  
 DB 363 ATCATGGAAGCTCATTTGGAAGTGTGACCTTTTTCATCCCTCACCCTCATTTGTGCTA 422  
 QY 361 CATGAGAGATCATTTATGAGGGCAAAAGATTAATGTTCTCGATAGAAAATTTATCAAG 420  
 DB 423 CATGAGAGATCATTTATGAGGGCAAAAGATTAATGTTCTCGATAGAAAATTTATCAAG 482  
 QY 421 CTGAGAGATTTGGAAGAAAGCAAAACCCAGCTCACTTGTTCGAAAGAGAGAGGTG 480  
 DB 483 CTGAGAGATTTGGAAGAAAGCAAAACCCAGCTCACTTGTTCGAAAGAGAGAGGTG 542  
 QY 481 GAGCAACAAGGCTTTTGCATTTGGGGCAACATGATGCGAGTCTTGCACTTGCATTCAGA 540  
 DB 543 GAGCAACAAGGCTTTTGCATTTGGGGCAACATGATGCGAGTCTTGCACTTGCATTCAGA 602  
 QY 541 AGATCACTTCAAGAGTAATCCAAAGGCC 570  
 |||||||||||||||||||||||||||||

DB 603 AGATCACTTCAAGAGTAATCCAAAGGCC 632

RESULT 2

ID ABA08605 standard; cDNA; 1097 BP.

XX ABA08605;

DT 11-JAN-2002 (first entry)

XX Human LK-4p homologue-encoding cDNA, SEQ ID NO:381.

XX Human; cytokine; cell proliferation; cell differentiation; growth factor;  
 KW hemotopolesis regulation; tissue growth; immunomodulator; activin;  
 KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;  
 KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;  
 KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;  
 KW chronic inflammatory condition; proliferative retinopathy;  
 KW atherosclerosis; coronary heart disease; arterial ischaemia;  
 KW bone disorder; osteoporosis; vascular growth disorder;  
 KW tissue regeneration; wound healing; infection; immune disorder;  
 KW cell culture; drug screening; gene therapy; antiinflammatory;  
 KW antisthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
 KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
 KW antifungal; vulnereary; antitumor; ss.

XX Homo sapiens.

PN W0200157188-A2.

PD 09-AUG-2001.

PF 05-FEB-2001; 2001MO-US03800.

PR 03-FEB-2000; 2000US-0496914.

PR 27-APR-2000; 2000US-0560875.

PA (HYSE-) HYSEQ INC.

PI Tang YT, Liu C, Drmanac RT;

DR MPI; 2001-457740/49.

DR P-PSDB; ABB11361.

PT Human proteins and DNA encoding sequences useful for preventing,  
 PT treating or ameliorating a medical condition in a mammalian subject  
 PT e.g. arthritis and cancer -

XX Claim 1; Page 473; 1963pp; English.

XX Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
 CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
 CC invention also relates to vectors and recombinant host cells comprising a  
 CC nucleotide of the invention, methods of producing the novel polypeptides,  
 CC antibodies against the polypeptides, methods of detecting the nucleotides  
 CC or polypeptides in a sample, and methods of identifying compounds which  
 CC bind to polypeptides of the invention. Although novel, many of the  
 CC polypeptides of the invention have homology to known proteins, thereby  
 CC giving an insight into their probable biological activities, and hence  
 CC potential therapeutic applications. The polypeptides of the invention may  
 CC have various activities, including cytokine, cell proliferation or cell  
 CC differentiation activities; stem cell growth factor activity;  
 CC haematopoiesis regulatory activity; tissue growth activity;  
 CC immunomodulatory activity; activin- or inhibin-related activities;  
 CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
 CC thrombolytic activities; receptor or ligand activities; or may be  
 CC involved in oncogenesis, cancer cell proliferation or metastasis.  
 CC Depending on their biological activities, polypeptides and nucleotides of  
 CC the invention are useful for preventing, treating or ameliorating medical  
 CC conditions, e.g., by protein or gene therapy. Such conditions include  
 CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
 CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),

CC proliferative retinopathy, atherosclerosis, coronary heart disease, arterial ischemia, bone disorders (e.g., osteoporosis), and abnormal CC vascular growth. Polypeptides involved with tissue regeneration and CC repair (or nucleic acids encoding them) may be used to promote wound healing (e.g., of burns, incisions and ulcers), while those with CC immunomodulatory activities may be used in the treatment of viral, CC bacterial and fungal infections in addition to immune disorders. CC Polypeptides with growth factor activity may be used in cell cultures to CC promote cell growth. For example, such polypeptides may be used to CC manipulate stem cells in culture to give rise to neuroepithelial cells CC that can be used to augment or replace cells damaged by illness, CC autoimmune disease or accidental damage. The polypeptides and nucleotides CC may also be used in the diagnosis of the above conditions, and in drug CC screening techniques. The present sequence represents a cDNA encoding a CC novel human polypeptide of the invention.

xx Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1097;

Best Local Similarity 99.8%; Pred. No. 5.2e-166; Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGCGGCTCACAAGATGATGATTTCTTC  
DB 269 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGCGGCTCACAAGATGATGATTTCTTC  
QY 61 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTGTGTGACCTGGCCATTCACATC  
DB 329 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTGTGTGACCTGGCCATTCACATC  
QY 121 TGGAGATTGGAAGCTTCAGCTGACTGTGGCCCTTTTCAGAGTCTGCTTCATTTAC  
DB 389 TGGAGATTGGAAGCTTCAGCTGACTGTGGCCCTTTTCAGAGTCTGCTTCATTTAC  
QY 181 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGTGCTGCTGTTGG 240  
DB 449 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGTGCTGCTGTTGG 508  
QY 241 ATCTATGGAAGCTTCAGCTGACTGTGGCCCTTTTCATCTCCTCATTTGCTCA 300  
DB 509 ATCTATGGAAGCTTCAGCTGACTGTGGCCCTTTTCATCTCCTCATTTGCTCA 568  
QY 301 ATCATCACCTATCTTACTGCGAGATCACAGAGGAGAAATTATGATTAAGGCTGTC 360  
DB 569 ATCATCACCTATCTTACTGCGAGATCACAGAGGAGAAATTATGATTAAGGCTGTC 628  
QY 361 CATGAGCAGATCATTAATGAGGGCAAAAGATTAATGCTCATAGAAAAATTGATCAAG 420  
DB 629 CATGAGCAGATCATTAATGAGGGCAAAAGATTAATGCTCATAGAAAAATTGATCAAG 688  
QY 421 CTGCAAGATATGAGAAAGCAAAACCCAGCTCACTTGTCTGAAAAGAGAGGCTG 480  
DB 689 CTGCAAGATATGAGAAAGCAAAACCCAGCTCACTTGTCTGAAAAGAGAGGCTG 748  
QY 481 GAGCAACAAGGCTTTTGGATTGGGGGAACATGATGAGTCTGACTTGGAGATAGA 540  
DB 749 GAGCAACAAGGCTTTTGGATTGGGGGAACATGATGAGTCTGACTTGGAGATAGA 808  
QY 541 AGATCAGTTCAAGAGGTAATCCAAAGGCC 570  
DB 809 AGATCAGTTCAAGAGGTAATCCAAAGGCC 838

RESULT 3  
AAK53221  
ID AAK53221 standard; cDNA; 1097 BP.

xx AAK53221;

xx 06-NOV-2001 (first entry)

xx Human polynucleotide SEQ ID NO 2750.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukemia;  
KW nervous system disorder; arthritis; inflammation; ss.

xx Homo sapiens.

xx W0200157190-AZ.

xx 09-AUG-2001.

xx 05-FEB-2001; 2001WO-US04098.

xx 03-FEB-2000; 2000US-0496914.

xx 27-APR-2000; 2000US-0560875.

xx 20-JUN-2000; 2000US-0596075.

xx 19-JUL-2000; 2000US-0620325.

xx 01-SEP-2000; 2000US-0654936.

xx 15-SEP-2000; 2000US-0663561.

xx 20-OCT-2000; 2000US-0693325.

xx 30-NOV-2000; 2000US-0728422.

xx (HYSE-) HYSEQ INC.

xx Tang YR, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;  
xx Zhao QJ, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
xx Xue AJ, Yang Y, Wejhrman T, Goodrich R;  
xx WPI; 2001-476283/51.  
xx P-PSDB; AAM80088.

xx Nucleic acids encoding polypeptides with cytokine-like activities,  
xx useful in diagnosis and gene therapy -  
xx Claim 1; Page 4962; 6221pp; English.

CC The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
CC (AAM80020) are omitted as the relevant pages from the sequence listing  
CC were missing at the time of publication.

xx Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1097;

Best Local Similarity 99.8%; Pred. No. 5.2e-166; Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGCGGCTCACAAGATGATGATTTCTTC 60  
DB 269 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGCGGCTCACAAGATGATGATTTCTTC 328  
QY 61 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTGTGTGACCTGGCCATTCACATC 120  
DB 329 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTGTGTGACCTGGCCATTCACATC 388  
QY 121 TGGAGATTGGAAGCTTCAGCTGACTGTGGCCCTTTTCAGAGTCTGCTTCATTTAC 180  
DB 389 TGGAGATTGGAAGCTTCAGCTGACTGTGGCCCTTTTCAGAGTCTGCTTCATTTAC 448  
QY 181 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGTGCTGCTGTTGG 240  
DB 449 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGTGCTGCTGTTGG 508



PD 09-AUG-2001.  
XX  
PF 05-FEB-2001; 2001WO-US04098.  
XX  
PR 03-FEB-2000; 2000US-0496914.  
XX 27-APR-2000; 2000US-0560875.  
PR 20-JUN-2000; 2000US-0598075.  
PR 19-JUL-2000; 2000US-0620325.  
PR 01-SEP-2000; 2000US-0654936.  
PR 15-SEP-2000; 2000US-0663561.  
PR 20-OCT-2000; 2000US-0693325.  
PR 30-NOV-2000; 2000US-0728422.  
XX  
XX (HYSE-) HYSEQ INC.  
XX  
PI Tang YF, Liu C, Dormanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;  
PI Zhao QJ, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;  
XX  
XX WPI: 2001-476283/51.  
DR P-PSDB; AAM79104.  
XX  
XX Nucleic acids encoding polypeptides with cytokine-like activities,  
PT useful in diagnosis and gene therapy -  
XX  
PS Claim 1; Page 2615-2616; 6221pp; English.  
XX  
XX The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAW80302) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
CC (AAM80020) are omitted as the relevant pages from the sequence listing  
CC were missing at the time of publication.  
XX  
XX Sequence 1312 BP; 370 A; 286 C; 287 G; 369 T; 0 other;  
SQ

Query Match 99.7%; Score 568.4; DB 22; Length 1312;  
Best Local Similarity 99.8%; Pred. No. 5.8e-166;  
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCCTCCAGCAAAAGCCGCGGGCCTCCACAGATGATGACTTTCTTC 60  
DB 294 ATGATGAATTTCCAGCCTCCAGCAAAAGCCGCGGGCCTCCACAGATGATGACTTTCTTC 353  
QY 61 ATCTCTGCTCTTTTCCCATCTTTACCCGCGGGGCTTTGACACCCCTGGCATCACCATC 120  
DB 354 ATCTCTGCTCTTTTCCCATCTTTACCCGCGGGGCTTTGACACCCCTGGCATCACCATC 413  
QY 121 TGGAGTTAAAGCTTCACTGACCTGCGCCCTTTTCGAGGCTCGCTCTTTCATTCAC 180  
DB 414 TGGAGTTAAAGCTTCACTGACCTGCGCCCTTTTCGAGGCTCGCTCTTTCATTCAC 473  
QY 181 TCCATCTACAGCTGATGACACACCCCTAATGATACAGGCGGCTGAGTGGGTTGTTGG 240  
DB 474 TCCATCTACAGCTGATGACACACCCCTAATGATACAGGCGGCTGAGTGGGTTGTTGG 533  
QY 241 ATCTATCGGAACCTCAATTTGGAAGTGTGCACTTTTTCATCCTCAACCTTCATTTGCTTA 300  
DB 534 ATCTATCGGAACCTCAATTTGGAAGTGTGCACTTTTTCATCCTCAACCTTCATTTGCTTA 593  
QY 301 ATCATCACTATCTTACTGCGAGATCACAAGAGGAGAGATTTATGATTAAGGCTGCTC 360  
DB 594 ATCATCACTATCTTACTGCGAGATCACAAGAGGAGAGATTTATGATTAAGGCTGCTC 653  
QY 361 CATGACAGATCATTAATGAGGGCAAAAGATTAATGTCTCTGATACAAAAATTGATCAAG 420

DB 654 CATGACAGATCATTAATGAGGGCAAAAGATTAATGTCTCTGATGAAAAAATTGATCAAG 713  
QY 421 CTGACAGATATGAGAGAGAACCAACCCAGCTCACTTGTCTGTGAAAAGAGAGAGCTG 480  
DB 714 CTGACAGATATGAGAGAGAACCAACCCAGCTCACTTGTCTGTGAAAAGAGAGAGCTG 773  
QY 481 GAGCAACAAGCGCTTTTGTGATTTGGGGGAACATGATGAGCTGACTTGTGGATCTAGA 540  
DB 774 GAGCAACAAGCGCTTTTGTGATTTGGGGGAACATGATGAGCTGACTTGTGGATCTAGA 833  
QY 541 AGATCAGTTCAAGAAAGGTAAATCCAAAGGCGC 570  
DB 834 AGATCAGTTCAAGAAAGGTAAATCCAAAGGCGC 863

RESULT 6  
AAH18131  
ID AAH18131 standard; cDNA; 1813 BP.  
XX  
XX AAH18131;  
AC  
XX 26-JUN-2001 (first entry)  
XX  
DE Human cDNA sequence SEQ ID NO:18001.  
XX  
XX Human; primer: detection; diagnosis; antisense therapy; gene therapy; ss.  
XX Homo sapiens.  
XX  
XX EP1074617-A2.  
PD 07-FEB-2001.  
XX  
XX 28-JUL-2000; 2000EP-0116126.  
PF  
XX 29-JUL-1999; 99JP-0248036.  
PR 27-AUG-1999; 99JP-0300253.  
PR 11-JAN-2000; 2000JP-0118776.  
PR 02-MAY-2000; 2000JP-0183767.  
PR 09-JUN-2000; 2000JP-0241899.  
XX  
XX (HELI-) HELIX RES INST.  
XX  
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
XX  
XX WPI: 2001-318749/34.  
DR  
XX  
XX Primer sets for synthesizing polynucleotides, particularly the 5602  
PT full-length cDNAs defined in the specification, and for the detection  
PT and/or diagnosis of the abnormality of the proteins encoded by the  
PT full-length cDNAs -  
PS  
XX Claim 8; SEQ ID 18001; 2537bp + CD ROW; English.  
XX  
XX The present invention describes primer sets for synthesizing 5602  
CC full-length cDNAs defined in the specification. Where a primer set  
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary  
CC to the complementary strand of a polynucleotide which comprises one of  
CC the 5602 nucleotide sequences defined in the specification, where the  
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination  
CC of an oligonucleotide comprising a sequence complementary to the  
CC complementary strand of a polynucleotide which comprises a 5'-end  
CC sequence and an oligonucleotide comprising a sequence complementary to a  
CC polynucleotide which comprises a 3'-end sequence, where the  
CC oligonucleotide comprises at least 15 nucleotides and the combination  
CC of the 5'-end sequence/3'-end sequence is selected from those defined in  
CC the specification. The primer sets can be used in antisense therapy and  
CC in gene therapy. The primers are useful for synthesizing polynucleotides,  
CC particularly full-length cDNAs. The primers are also useful for the  
CC detection and/or diagnosis of the abnormality of the proteins encoded by  
CC the full-length cDNAs. The primers allow obtaining of the full-length

CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and  
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to  
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632  
CC represent oligonucleotides, all of which are used in the exemplification  
CC of the present invention.

XX Sequence 1813 BP; 489 A; 400 C; 405 G; 519 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1813;  
Best Local Similarity 99.8%; Pred. No. 6.9e-166;  
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAGCCCTGGCGGCTCAGAGATGACTTTCTC 60  
DB 451 ATGATGAATTTCCAGCTCCGAGCAAGCCCTGGCGGCTCAGAGATGACTTTCTC 510  
QY 61 ATCTCTTGGCTTTTCCATCTTTCACCGGGGTCTTGGACCCCTGGCCATCACCATC 120  
DB 511 ATCTCTTGGCTTTTCCATCTTTCACCGGGGTCTTGGACCCCTGGCCATCACCATC 570  
QY 121 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTGGAGTCTGCTCTTCATTTCAC 180  
DB 571 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTGGAGTCTGCTCTTCATTTCAC 630  
QY 181 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGGCCCTGCTACCTGAGTGTGG 240  
DB 631 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGGCCCTGCTACCTGAGTGTGG 690  
QY 241 ATCTATCGGAACCTCATATGGAAGTGTGACTTTCTTTCATCTCCACCCCTATTTGCTCA 300  
DB 691 ATCTATCGGAACCTCATATGGAAGTGTGACTTTCTTTCATCTCCACCCCTATTTGCTCA 750  
QY 301 ATCATACCTATCTCTTCTGCGAGATCACAGAGGGAAGATTATGATTAAGCTGCTC 360  
DB 751 ATCATACCTATCTCTTCTGCGAGATCACAGAGGGAAGATTATGATTAAGCTGCTC 810  
QY 361 CATGACGAGATCATTAATGAGGGCAAGATAAATGTTCTGTATGAAAAATGATCAAG 420  
DB 811 CATGACGAGATCATTAATGAGGGCAAGATAAATGTTCTGTATGAAAAATGATCAAG 870  
QY 421 CTGAGGATTTGGAGGAAGAAACCCCACTGCTTGTCTGGAAAAGAGAGAGCTG 480  
DB 871 CTGAGGATTTGGAGGAAGAAACCCCACTGCTTGTCTGGAAAAGAGAGAGCTG 930  
QY 481 GAGCAACAAGGCTTTTGGATTTGGGGGAACATGATGAGCTTGTGACTTGGCATTCAGA 540  
DB 931 GAGCAACAAGGCTTTTGGATTTGGGGGAACATGATGAGCTTGTGACTTGGCATTCAGA 990  
QY 541 AGATCAGTTCAAGAGGTAATCCAAAGGCC 570  
DB 991 AGATCAGTTCAAGAGGTAATCCAAAGGCC 1020

RESULT 7  
AAF82462  
ID AAF82462 standard; cDNA; 1960 BP.

XX AAF82462;

DT 29-JUN-2001 (first entry)

XX Human CASB6411-related cDNA #1.

XX Human: CASB6411; vaccine; gene therapy; immunoprophylaxis;

XX ovarian cancer; colon cancer; autoimmune disease; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX CDS 1..1317

XX FT /\*tag- a

XX FT /partial

XX FT /note- "this sequence does not contain a start codon"

XX WO200123417-A2.

XX 05-APR-2001.

XX 27-SEP-2000; 2000WO-EP09500.

XX 30-SEP-1999; 99GB-0023154.

XX 07-JUL-2000; 2000GB-0016839.

XX (SMK) SMITHKLINE BEECHAM BIOLOGICALS.

XX vinals De Bassols VC;

XX WPI: 2001-316133/33.

XX P-PDSB; AAB83081.

XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
XX prophylactic and therapeutic treatment of cancers, particularly ovarian  
XX and colon cancers, autoimmune diseases and related conditions

XX Claim 32; Page 65-66; 95pp; English.

XX The present sequence is provided in a specification relating  
XX to CASB6411 polypeptides comprising a sequence having at least 70%  
XX identity to a sequence of 460 or 154 amino acids fully defined in  
XX the specification. CASB6411 polypeptides and polynucleotides are  
XX useful for treating a subject by immunoprophylaxis or therapy.  
XX The CASB6411 polypeptides are useful in diagnostics, and as  
XX vaccines for prophylactic and therapeutic treatment of cancers,  
XX particularly ovarian and colon cancers, autoimmune diseases and related  
XX conditions. CASB6411 polypeptides are also useful for the  
XX structure-based design of agonists, antagonists or inhibitors of the  
XX polypeptide.

XX Sequence 1960 BP; 515 A; 439 C; 447 G; 559 T; 0 other;

Query Match 99.7%; Score 568.4; DB 22; Length 1960;  
Best Local Similarity 99.8%; Pred. No. 7.2e-166;  
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAGCCCTGGCGGCTCAGAGATGACTTTCTC 60  
DB 745 ATGATGAATTTCCAGCTCCGAGCAAGCCCTGGCGGCTCAGAGATGACTTTCTC 804  
QY 61 ATCTCTTGGCTTTTCCATCTTTCACCGGGGTCTTGGACCCCTGGCCATCACCATC 120  
DB 805 ATCTCTTGGCTTTTCCATCTTTCACCGGGGTCTTGGACCCCTGGCCATCACCATC 864  
QY 121 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTGGAGTCTGCTCTTCATTTCAC 180  
DB 865 TGGAGATTGAAGCCTTCAGCTGAGCTGGCCCTTTTGGAGTCTGCTCTTCATTTCAC 924  
QY 181 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGGCCCTGCTACCTGAGTGTGG 240  
DB 925 TCCATCTACAGCTGGATCGACACCCCTAAGTACACGGCCCTGCTACCTGAGTGTGG 984  
QY 241 ATCTATCGGAACCTCATATGGAAGTGTGACTTTCTTTCATCTCCACCCCTATTTGCTCA 300  
DB 985 ATCTATCGGAACCTCATATGGAAGTGTGACTTTCTTTCATCTCCACCCCTATTTGCTCA 1044  
QY 301 ATCATACCTATCTCTTCTGCGAGATCACAGAGGGAAGATTATGATTAAGCTGCTC 360  
DB 1045 ATCATACCTATCTCTTCTGCGAGATCACAGAGGGAAGATTATGATTAAGCTGCTC 1104  
QY 361 CATGACGAGATCATTAATGAGGGCAAGATAAATGTTCTGTATGAAAAATGATCAAG 420  
DB 1105 CATGACGAGATCATTAATGAGGGCAAGATAAATGTTCTGTATGAAAAATGATCAAG 1164  
QY 421 CTGAGGATTTGGAGGAAGAAACCCCACTGCTTGTCTGGAAAAGAGAGAGCTG 480  
DB 1165 CTGAGGATTTGGAGGAAGAAACCCCACTGCTTGTCTGGAAAAGAGAGAGAGCTG 1224



QY 481 GAGCAACAAGCCTTTTGCATTGGGGAGACATGATGCGACTTGCATTCGATCTAGA 540  
|||||  
Db 1225 GAGCAACAAGCCTTTTGCATTGGGGAGACATGATGCGACTTGCATTCGATCTAGA 1284  
QY 541 AGATCAGTTCAAGAAGTAATCCAAAGGCC 570  
|||||  
Db 1285 AGATCAGTTCAAGAAGTAATCCAAAGGCC 1314

RESULT 8  
AA64684  
ID AA64684 standard; cDNA: 2243 BP.  
AC AA64684;  
XX  
DT 02-JAN-2001 (first entry)  
XX  
XX cDNA encoding a human leukocyte and blood related protein (LBAP).  
XX  
XX Human: leukocyte and blood related protein; LBAP; arteriosclerosis;  
KM cell proliferative disorder; actinic keratosis; atherosclerosis;  
KM buritis; cirrhosis; hepatitis; mixed connective tissue disease; MCTD;  
KM myelofibrosis; paroxysmal nocturnal hemoglobinuria; cancer;  
KM adenocarcinoma; leukemia; lymphoma; melanoma; myeloma; sarcoma;  
KM teratocarcinoma; autoimmune disorder; inflammatory disorder;  
KM acquired immunodeficiency syndrome; AIDS; Addison's disease;  
KM adult respiratory distress syndrome; allergy; ankylosing spondylitis;  
KM amyloidosis; anaemia; asthma; autoimmune haemolytic anaemia; infection;  
KM Werner syndrome; haemodialysis; extracorporeal circulation; trauma; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 109..1272  
FT /\*tag= a  
FT /product= "leukocyte and blood related protein (LBAP)"  
FT sig\_peptide 109..261  
FT /\*tag= b  
XX  
PN WC200052161-A2.  
XX  
PD 08-SEP-2000.  
XX  
PE 29-FEB-2000; 2000WO-US05153.  
XX  
PR 01-MAR-1999; 99US-0122080.  
XX  
PA (INCY-) INCYTE PHARM INC.  
XX  
PI Lal P, Yue H, Hillman JL, Lu DM, Baughn MR, Tang YT, Azimzai Y;  
XX  
DR WPI: 2000-587310/55.  
XX  
DR -P-PSDB: AAB08764.  
XX  
XX  
XX Leukocyte and blood associated proteins and polynucleotides encoding  
PT them, useful for diagnosis, treatment and prevention of  
PT autoimmune/inflammatory disorders and cell proliferative disorders  
PT including cancer -  
XX  
PS Claim 4; Page 68-69; 70pp; English.  
XX  
XX The present sequence encodes a human leukocyte and blood related  
CC protein, designated LBAP. LBAP polynucleotides and polypeptides are  
CC useful for treating or preventing a disorder associated with decreased  
CC expression or activity of LBAP including a cell proliferative disorder  
CC such as actinic keratosis, arteriosclerosis, atherosclerosis, buritis,  
CC cirrhosis, hepatitis, mixed connective tissue disease (MCTD),  
CC myelofibrosis, paroxysmal nocturnal hemoglobinuria, etc., cancers  
CC including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma,  
CC sarcoma, teratocarcinoma and in particular cancers of the adrenal  
CC gland, bladder, bone, bone marrow, brain, breast, cervix, etc., and  
CC an autoimmune/inflammatory disorder such as acquired immunodeficiency  
CC syndrome (AIDS), Addison's disease, adult respiratory distress syndrome,

CC allergies, ankylosing spondylitis, amyloidosis, anaemia, asthma,  
CC atherosclerosis, autoimmune haemolytic anaemia, etc., Werner syndrome,  
CC complications of cancer, haemodialysis, and extracorporeal circulation,  
CC viral, bacterial, fungal, parasitic, protozoan, and helminthic  
CC infections, and trauma.  
XX  
SQ Sequence 2243 BP; 602 A; 500 C; 520 G; 621 T; 0 other;

Query Match 99.7%; Score 568.4; DB 21; Length 2243;  
Best Local Similarity 99.8%; Pred. No. 7.7e-166;  
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGATGAATTTCCAGCCTCCGAGCAAGCCTGGCGGCGCTCCACAGATGATGACTTTCTTC 60  
|||||  
Db 700 ATGATGAATTTCCAGCCTCCGAGCAAGCCTGGCGGCGCTCCACAGATGATGACTTTCTTC 759  
QY 61 ATCTTCTGCTCTTTTCCCATCTTTTCACGGGGCTTTGTGCACCCCTGGCATCACATC 120  
|||||  
Db 760 ATCTTCTGCTCTTTTCCCATCTTTTCACGGGGCTTTGTGCACCCCTGGCATCACATC 819  
QY 121 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCAGAGCTTCGCTCTTCATTTCAC 180  
|||||  
Db 820 TGGAGATTGAAGCCTTCAGCTGACTGTGGCCCTTTTCAGAGCTTCGCTCTTCATTTCAC 879  
QY 181 TCCATCTCAGCTGGATGACACACCTTAAGTACACGGCCCTGGCTACCTGTGGGTTTGG 240  
|||||  
Db 880 TCCATCTCAGCTGGATGACACACCTTAAGTACACGGCCCTGGCTACCTGTGGGTTTGG 939  
QY 241 ATCTATCGGAACCTTCATGGAAGTGTGCACCTTTTCATCCTCACCCCTATTTGTGCTA 300  
|||||  
Db 940 ATCTATCGGAACCTTCATGGAAGTGTGCACCTTTTCATCCTCACCCCTATTTGTGCTA 999  
QY 301 ATCATCACCCTATCTTTACTGCGACATCCAGAGGAGAGAGATTTATAGGCTGCTC 360  
|||||  
Db 1000 ATCATCACCCTATCTTTACTGCGACATCCAGAGGAGAGAGATTTATAGGCTGCTC 1059  
QY 361 CATGAGCAGATCATTAATGAGGGGCAAGATTAATGCTTCGATGAGAAAATTGATCAAG 420  
|||||  
Db 1060 CATGAGCAGATCATTAATGAGGGGCAAGATTAATGCTTCGATGAGAAAATTGATCAAG 1119  
QY 421 CTGCAGATATGAGAGAAAGCAAAACCCACGCTCACTGTTCTGGAAGAGAGAGGTG 480  
|||||  
Db 1120 CTGCAGATATGAGAGAAAGCAAAACCCACGCTCACTGTTCTGGAAGAGAGAGGTG 1179  
QY 481 GAGCAACAAGCCTTTTGCATTGGGGAGACATGATGCGACTTGCATTCGATCTAGA 540  
|||||  
Db 1180 GAGCAACAAGCCTTTTGCATTGGGGAGACATGATGCGACTTGCATTCGATCTAGA 1239  
QY 541 AGATCAGTTCAAGAAGTAATCCAAAGGCC 570  
|||||  
Db 1240 AGATCAGTTCAAGAAGTAATCCAAAGGCC 1269

RESULT 9  
AAF82460  
ID AAF82460 standard; cDNA: 2407 BP.  
XX  
AC AAF82460;  
XX  
DT 29-JUN-2001 (first entry)  
XX  
XX Human CASB6411 cDNA.  
XX  
XX Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
KM ovarian cancer; colon cancer; autoimmune disease; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 382..1764  
FT /\*tag= a  
FT /product= "CASB6411"  
XX

```

PN WO200123417-A2.
XX
PD 05-APR-2001.
XX
XX 27-SEP-2000; 2000MO-EP09500.
XX
XX 30-SEP-1999; 99GB-0023154.
PR 07-JUL-2000; 2000GB-0016839.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Vinals De Bassols YC;
XX
XX WPI; 2001-316133/73.
DR P-PSDB; AAB83079.
XX
XX
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions .
XX
XX Claim 11; Page 63-64; 95pp; English.
PS
XX
CC The present sequence encodes human CASB6411 polypeptide. The
CC invention relates to CASB6411 polypeptides comprising a sequence
CC having at least 70% identity to a sequence of 460 or 154 amino acids
CC fully defined in the specification. CASB6411 polypeptides and
CC polynucleotides are useful for treating a subject by immunoprophylaxis
CC or therapy. The CASB6411 polypeptides are useful in diagnostics, and
CC as vaccines for prophylactic and therapeutic treatment of cancers, and
CC particularly ovarian and colon cancers, autoimmune diseases and related
CC conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide. The present sequence may be alternatively spliced to
CC generate a sequence encoding a truncated CASB6411 protein.
XX
SQ Sequence 2407 BP; 635 A; 557 C; 546 G; 663 T; 0 other:
Query Match 99.7%; Score 568.4; DB 22; Length 2407;
Best Local Similarity 99.8%; Pred. No. 8e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 ATGATGAATTTCCAGCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTTCTTC 60
DB 1192 ATGATGAATTTCCAGCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTTCTTC 1251
QY 61 ATCTCTGCTCTTTTCCATCTTCCACCGGGGCTGTGACCCCGGCATCACCATC 120
DB 1252 ATCTCTGCTCTTTTCCATCTTCCACCGGGGCTGTGACCCCGGCATCACCATC 1311
QY 121 TGGAGATTGAAGCCTCAGCTGACTGTGGCCCTTTTGAAGTCTGCTCTTCATTTCAC 180
DB 1312 TGGAGATTGAAGCCTCAGCTGACTGTGGCCCTTTTGAAGTCTGCTCTTCATTTCAC 1371
QY 181 TCCATCTACGCTGATGACACACCTTAAGTACACGGCTGGCTACCTGTGGTTGG 240
DB 1372 TCCATCTACGCTGATGACACACCTTAAGTACACGGCTGGCTACCTGTGGTTGG 1431
QY 241 ATCTATCGGAACCTCAATTGGAAGTGCACCTTTTATCCTCCACCCCATTTGCTCA 300
DB 1432 ATCTATCGGAACCTCAATTGGAAGTGCACCTTTTATCCTCCACCCCATTTGCTCA 1491
QY 301 ATCATCACCTATCTTTACTGTCAGATCACAGAGGAAGAAATTTAGATAGGCTGCTC 360
DB 1492 ATCATCACCTATCTTTACTGTCAGATCACAGAGGAAGAAATTTAGATAGGCTGCTC 1551
QY 361 CATGACACGATCATTAATGAGGGCAAGATAAATGTTCTCGATAGAAAAATGATCAAG 420
DB 1552 CATGACACGATCATTAATGAGGGCAAGATAAATGTTCTCGATAGAAAAATGATCAAG 1611
QY 421 CTGACAGATATGAGAAAGAAAGCAAAACCCAGCTCAGCTTCTTGTGAAAGAGAGGCTG 480
DB 1612 CTGACAGATATGAGAAAGAAAGCAAAACCCAGCTCAGCTTCTTGTGAAAGAGAGGCTG 1671
```

```

QY 481 GAGCAACAGGCTTTTTCATTTGGGGGAACATGATGGCAGTCTTGATCGATCTAGA 540
DB 1672 GAGCAACAGGCTTTTTCATTTGGGGGAACATGATGGCAGTCTTGATCGATCTAGA 1731
QY 541 AGATCAGTTCAAGAGGATATCCAGGGCC 570
DB 1732 AGATCAGTTCAAGAGGATATCCAGGGCC 1761

RESULT 10
AAF82461
ID AAF82461 standard; cDNA; 2521 BP.
XX
XX AAF82461;
AC
XX
XX 29-JUN-2001 (first entry)
DT
XX
XX Alternatively spliced human CASB6411 cDNA encoding truncated protein.
DE
XX
XX Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
KM ovarian cancer; colon cancer; autoimmune disease; isoform;
KM alternative splicing; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH CDS 382..846
FT /*tag= a
FT /product= "truncated CASB6411"
XX
XX WO200123417-A2.
XX
XX 05-APR-2001.
XX
XX 27-SEP-2000; 2000MO-EP09500.
PE
XX
XX 30-SEP-1999; 99GB-0023154.
PR 07-JUL-2000; 2000GB-0016839.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
PA
XX
XX Vinals De Bassols YC;
PI
XX
XX WPI; 2001-316133/73.
DR P-PSDB; AAB83080.
XX
XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions .
XX
XX Claim 11; Page 64-65; 95pp; English.
PS
XX
CC The present sequence encodes a truncated CASB6411 polypeptide. It
CC is generated by alternative splicing of the full length human cDNA
CC sequence of CASB6411. The invention relates to CASB6411 polypeptides
CC comprising a sequence having at least 70% identity to a sequence of
CC 460 or 154 amino acids fully defined in the specification. CASB6411
CC polypeptides and polynucleotides are useful for treating a subject by
CC immunoprophylaxis or therapy. The CASB6411 polypeptides are useful in
CC diagnostics, and as vaccines for prophylactic and therapeutic treatment
CC of cancers, particularly ovarian and colon cancers, autoimmune diseases
CC and related conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide.
XX
SQ Sequence 2521 BP; 662 A; 583 C; 583 G; 693 T; 0 other:
Query Match 99.7%; Score 568.4; DB 22; Length 2521;
Best Local Similarity 99.8%; Pred. No. 8.2e-166;
Matches 569; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 ATGATGAATTTCCAGCTCCGAGCAAAAGCCTGGCGGCTCAGATGATGACTTTCTTC 60
```

PT	Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer -
XX	Claim 1; Page 3912; 11750pp; English.
PS	The invention relates to an isolated nucleic acid molecule (I) comprising
CC	a nucleotide sequence given in tables 1-9 (ABY00010-ABV62213) of the
CC	specification or its complement. (I) is useful for:
CC	(a) assessing whether a patient is afflicted with prostate cancer;
CC	(b) monitoring the progression of prostate cancer in a patient;
CC	(c) assessing the efficacy of a test compound to inhibit prostate cancer in a patient;
CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;
CC	(e) selecting a composition for inhibiting prostate cancer in a patient;
CC	(f) assessing the prostate cell carcinogenic potential of a compound;
CC	(g) determining whether prostate cancer has metastasized in a patient;
CC	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;
CC	(i) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX	Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;
SO	
Query Match	96.2%; Score 548.4; DB 23; Length 1194;
Best Local Similarity	98.8%; Pred. No. 9e-160;
Matches 563; Conservative %	0; Mismatches 6; Indels 1; Gaps 1;
Dy	1 ATGATGAATTTCACAGCCTCCGAGCAAAACCCTGGCGGCTCACAGATAGACTTCTTC 60
Dy	531 ATGATGAATTTCACAGCCTCCGAGCAAAACCCTGGCGGCTCACAGATAGACTTCTTC 590
Dy	61 ATCTCTTGCTCTTTTTCCTCATCTTTCACCGGGGTCTTGTCACCCCTGCATCCATC 120
Dy	591 ATCTCTTGCTCTTTTTCCTCATCTTTCACCGGGGTCTTGTCACCCCTGCATCCATC 650
Dy	121 TGAGATGTAAGCCTTCAGCTGACTGCTGCGCCCTTTTGAGGCTCTGCCCTCTTCATC 180
Dy	651 TGAGATGTAAGCCTTCAGCTGACTGCTGCGCCCTTTTGAGGCTCTGCCCTCTTCATC 710
Dy	181 TTCACATCAACCTGGATCGACACCTTAGTACAAGCGCTGGCTACCTGGGTGTGG 240
Dy	711 TTCACATCAACCTGGATCGACACCTTAGTACAAGCGCTGGCTACCTGGGTGTGG 770
Dy	241 ATCTATCGGACCTCATTTGAGAAGTGTGACATCTTTTCATCCCTCACCCCTCATTTGTCTA 300
Dy	771 ATCTATCGGACCTCATTTGAGAAGTGTGACATCTTTTCATCCCTCACCCCTCATTTGTCTA 830
Dy	301 ATCATCAACCTATCTTTACTGGCAGATCAACAGAGGGAAGAAATATGATAAGCGTGTCTC 360
Dy	831 ATCATCAACCTATCTTTACTGGCAGATCAACAGAGGGAAGAAATATGATAAGCGTGTCTC 890
Dy	361 CATGACGATCATTTAATGAGGCGAAGATAAATGTTCTCGATGAAAAATTTGATCAAG 420
Dy	891 CATGACGATCATTTAATGAGGCGAAGATAAATGTTCTCGATGAAAAATTTGATCAAG 950
Dy	421 CTGAGAGTATGGAAGAAAAGCAAACCCGAGCTACTGTTCTGGAAGGAGAAGGNG 480
Dy	951 CTGAGAGTATGGAAGAAAAGCAAACCCGAGCTACTGTTCTGGAAGGAGAAGGNG 1009
Dy	481 GAGCAACAAGGCTTTTTCATTTTGGGGGGAACATGATGAGCAGTCTTGACTTGGCATCTAGA 540
Dy	1010 GAGCAACAAGGCTTTTTCATTTTGGGGGGAACATGATGAGCAGTCTTGACTTGGCATCTAGA 1069
Dy	541 AGATCAGTTCAAGAAAGTAAATCCAAGGCC 570
Dy	1070 CGATCAGTTCAAGAAAGTAAATCCAAGGCC 1099
RESULT 12	
ABV25683	
ID	ABV25683 standard; cDNA; 1194 BP.

AC ABV25683;  
XX  
DT 16-SEP-2002 (first entry)  
XX  
DE Human prostate expression marker cDNA 25674.  
XX  
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN W0200160860-A2.  
XX  
PD 23-AUG-2001.  
PF 20-FEB-2001; 2001WO-US05171.  
XX  
PR 17-FEB-2000; 2000US-183319P.  
PR 16-MAR-2000; 2000US-189862P.  
PR 25-MAY-2000; 2000US-207454P.  
PR 09-JUN-2000; 2000US-211314P.  
PR 18-JUL-2000; 2000US-219007P.  
PR 13-DEC-2000; 2000US-255281P.  
XX  
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
PI Schlegel R, Endege WO, Monahan JE;  
XX  
XX WPI; 2001-662795/76.  
XX  
PT Novel isolated nucleic acid molecule associated with cancerous state of  
PT prostate cells and correlating with presence of prostate cancer, useful  
XX for detecting presence of prostate cancer, stage of prostate cancer -  
XX  
PS Claim 1; Page 5146-5147; 11750pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for:  
CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate  
CC cancer in a patient;  
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
CC in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a  
CC patient;  
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
SO Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;  
XX  
Query Match 96.2%; Score 548.4; DB 23; Length 1194;  
Best Local Similarity 98.8%; Pred. No. 9e-160;  
Matches 563; Conservative 0; Mismatches 6; Indels 1; Gaps 1;  
XX  
QY 1 ATGATGAATTTCCAGCTCCGAGCAAGCCTGGGGGCTCCACGATGATGACTTTCTC 60  
DB 531 ATGATGAATTTCCAGCTCCGAGCAAGCCTGGGGGCTCCACGATGATGACTTTCTC 590  
QY 61 ATCTTTGCTCTTTTCCCATTTTACCGGGGCTTTGACACCTGGCCATCACATC 120  
DB 591 ATCTTTGCTCTTTTCCCATTTTACCGGGGCTTTGACACCTGGCCATCACATC 650  
QY 121 TGGAGATGGAAGCCTTCACTGAGTGGCCCTTTTGGAGGCTGCTCTCTTCATTAC 180  
DB 651 TGGAGATGGAAGCCTTCACTGAGTGGCCCTTTTGGAGGCTGCTCTCTTCATTAC 710  
QY 181 TCCATCTACAGCTGGATGACACCCCTAAGTACAGAGGCTGCTCTGTTGGTTGG 240  
DB 711 TCCATCTACAGCTGGATGACACCCCTAAGTACAGAGGCTGCTCTGTTGGTTGG 770

QY 241 ATCTATCGGAACCTCATTTGGAAGTGTGCACTCTTTTTCATCTCCACCTCATTTGTCTA 300  
DB 771 ATCTATCGGAACCTCATTTGGAAGTGTGCACTCTTTTTCATCTCCACCTCATTTGTCTA 830  
QY 301 ATCTATCGACCTTATCTTTCTGCGACATCATCAGAGGAAGAAATTATGATTAAGCTCTC 360  
DB 831 ATCTATCGACCTTATCTTTCTGCGACATCATCAGAGGAAGAAATTATGATTAAGCTCTC 890  
QY 361 CATGAGCAGATCATTAATGAGGGCAAGATAAATGTTCTGATTAAGAAATTTGATCAAG 420  
DB 891 CATGAGCAGATCATTAATGAGGGCAAGATAAATGTTCTGATTAAGAAATTTGATCAAG 950  
QY 421 CTGCAGATATGAGAAAGAAAGCAAAACCCAGCTCACTGTTCTGGAAGAGAGAGTG 480  
DB 951 CTGCAGATATGAGAAAGAAAGCAAA-CCAGCTCACTGTTGACTGGAAGAGAGAGTG 1009  
QY 481 GAGCAACAAAGCTTTTTCATTTGGGGGACATGATGCACTTGTGCTTGCATCTAGA 540  
DB 1010 GAGCAACAAAGCTTTTTCATTTGGGGGACATGATGCACTTGTGCTTGCATCTAGA 1069  
QY 541 AGATCAGTTCAAGAAAGTAAATCCAAAGGCC 570  
DB 1070 CGATCAGTTCAAGAAAGTAAATCCAAAGGCC 1099  
XX  
RESULT 13  
ABV28278  
ID ABV28278 standard; cDNA; 1194 BP.  
XX  
AC ABV28278;  
XX  
DT 16-SEP-2002 (first entry)  
XX  
DE Human prostate expression marker cDNA 28269.  
XX  
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN W0200160860-A2.  
XX  
PD 23-AUG-2001.  
PF 20-FEB-2001; 2001WO-US05171.  
PR 17-FEB-2000; 2000US-183319P.  
PR 16-MAR-2000; 2000US-189862P.  
PR 25-MAY-2000; 2000US-207454P.  
PR 09-JUN-2000; 2000US-211314P.  
PR 18-JUL-2000; 2000US-219007P.  
PR 13-DEC-2000; 2000US-255281P.  
XX  
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
PI Schlegel R, Endege WO, Monahan JE;  
XX  
XX WPI; 2001-662795/76.  
XX  
PT Novel isolated nucleic acid molecule associated with cancerous state of  
PT prostate cells and correlating with presence of prostate cancer, useful  
XX for detecting presence of prostate cancer, stage of prostate cancer -  
XX  
PS Claim 1; Page 5881-5882; 11750pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for:  
CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate  
CC cancer in a patient;

CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
CC in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a patient;  
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;

Query Match 96.2%; Score 548.4; DB 23; Length 1194;  
Best Local Similarity 98.8%; Pred. No. 9e-160;

Matches 563; Conservative 0; Mismatches 6; Indels 1; Gaps 1;

QY 1 ATGATGAATTTCCAGCTCCGAGCAAGAGCTGGCGGCTCCAGATGATGATCTTCTTC  
DB 531 ATGATGAATTTCCAGCTCCGAGCAAGAGCTGGCGGCTCCAGATGATGATCTTCTTC  
QY 61 ATCTCTTGGCTTTTCCATCTTTCACCGGGCTTGTGACCTTGCCATCCATC  
DB 591 ATCTCTTGGCTTTTCCATCTTTCACCGGGCTTGTGACCTTGCCATCCATC  
QY 121 TGGAGATTGAAGCTTCAAGCTGAGTGGCCCTTTTCAGAGTCCCTCTTCATTCAC  
DB 651 TGGAGATTGAAGCTTCAAGCTGAGTGGCCCTTTTCAGAGTCCCTCTTCATTCAC  
QY 181 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGCTGAGTGGTGTGG  
DB 711 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGCTGCTGAGTGGTGTGG  
QY 241 ATCTATCGGAACCTGATGGAAGTGGACCTTTTCATCTTCACCTCATTTGGCA  
DB 771 ATCTATCGGAACCTGATGGAAGTGGACCTTTTCATCTTCACCTCATTTGGCA  
QY 301 ATCATCACCCTATCTTACTGCGAGATCACAGAGGAGGAATATGATTAAGGCTGCTC  
DB 831 ATCATCACCCTATCTTACTGCGAGATCACAGAGGAGGAATATGATTAAGGCTGCTC  
QY 361 CATGAGCAGATCATTAATGAGGCAAAAGATTAATGCTCTGATAGAAAATTTGATCAAG  
DB 891 CATGAGCAGATCATTAATGAGGCAAAAGATTAATGCTCTGATAGAAAATTTGATCAAG  
QY 421 CTGCGAGATGAGAGAAAGCAAAACCCAGCTCACTGTTCTGGAAGGAGAGGTG  
DB 951 CTGCGAGATGAGAGAAAGCAAAACCCAGCTCACTGTTCTGGAAGGAGAGGTG  
QY 481 GAGCAACAAGCTTTTTCATTTGGGGGAAACATGATGAGCTTGAATTTGATCTAGA  
DB 1010 GAGCAACAAGCTTTTTCATTTGGGGGAAACATGATGAGCTTGAATTTGATCTAGA  
QY 541 AGATCAGTTCAAGAAGATATCCAAAGGGCC 570  
DB 1070 CGATCAGTTCAAGAAGATATCCAAAGGGCC 1099

## RESULT 14

AA109919 standard; cDNA: 501 BP.

AA109919;

07-DEC-2001 (first entry)

XX Human breast cancer expressed polynucleotide 2376.  
XX Human breast cancer; cell marker; cytostatic; ss.  
XX Homo sapiens.  
XX WO200151628-A2.  
XX PD 19-JUL-2001.

XX 10-JAN-2001; 2001WO-0500798.  
XX 14-JAN-2000; 2000US-0176077.  
XX 14-MAR-2000; 2000US-0189167.  
XX 24-MAR-2000; 2000US-0192099.  
XX 29-MAR-2000; 2000US-0193480.  
XX 15-MAY-2000; 2000US-0205230.  
XX 09-JUN-2000; 2000US-0211315.  
XX 25-JUL-2000; 2000US-0220534.

(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

Lillie J, Xu Y, Wang Y, Steinmann K;

WPI; 2001-451856/48.

New peptide useful as a marker for the diagnosis of breast cancer -

Claim 1: Page 455; 3695pp; English.

The invention relates to human breast cancer expressed polynucleotides (AA107544-AA126789) and methods of assessing whether a patient is afflicted with breast cancer by examining the correlation between the expression of certain markers and the cancerous state of breast cells. The polynucleotides and encoded polypeptides are potential markers for detecting, diagnosing, monitoring, characterizing, treating and potentially preventing breast cancer. The polynucleotides and encoded polypeptides are also useful for isolating compounds with cytostatic activity.

Sequence 501 BP; 147 A; 101 C; 128 G; 122 T; 3 other;

Query Match 63.7%; Score 363; DB 22; Length 501;  
Best Local Similarity 98.4%; Pred. No. 2.2e-102;

Matches 366; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 199 GACACCCCTAAGTACACGCGCTGCTACCTGCTGCTTTGATCTATGGAACCTCAT  
DB 24 GCGCGCCGAGGTACACGCGCTGCTACCTGCTGCTTTGATCTATGGAACCTCAT  
QY 259 GGAAGTGTCACTTCTTTTCACTCCACCTCATTTGCTATCATCATCTATCTTAC  
DB 84 GGAAGTGTCACTTCTTTTCACTCCACCTCATTTGCTATCATCATCTATCTTAC  
QY 319 TGGCAGATCACAGAGGGAAGAAATATGATTAAGGCTCTCCAGAGCATCATTAAT  
DB 144 TGGCAGATCACAGAGGGAAGAAATATGATTAAGGCTCTCCAGAGCATCATTAAT  
QY 379 GAGGCGAAGATTAATGCTCTGATGAGAAAATTTGATCAAGCTGAGATTTGGAAG  
DB 204 GAGGCGAAGATTAATGCTCTGATGAGAAAATTTGATCAAGCTGAGATTTGGAAG  
QY 439 AAAGCAACCCAGCTCACTTGTCTGAAAGAGAGAGTGGAGCAAAAGCTTTTG  
DB 264 AAAGCAACCCAGCTCACTTGTCTGAAAGAGAGAGTGGAGCAAAAGCTTTTG  
QY 499 CATTTGGGGGAACATGATGAGCTTGTGATTTGATTTGATTTGATTTGATTTGAT  
DB 324 CATTTGGGGGAACATGATGAGCTTGTGATTTGATTTGATTTGATTTGATTTGAT  
QY 559 AATCCAAAGGGCC 570  
DB 384 AATCCAAAGGGCC 395

## RESULT 15

AA118591 standard; cDNA: 470 BP.

AA118591;

07-DEC-2001 (first entry)

